Merck Quick Ratio 2010-2025 | MRK

Historical quick ratio values for Merck (MRK) over the last 10 years.
Merck Quick Ratio Historical Data
Date Current Assets - Inventory Current Liabilities Quick Ratio
2025-03-31 $0.00B 0.00
2024-12-31 $32.67B $28.42B 1.15
2024-09-30 $34.12B $29.59B 1.15
2024-06-30 $31.74B $26.06B 1.22
2024-03-31 $24.94B $25.10B 0.99
2023-12-31 $25.81B $25.69B 1.01
2023-09-30 $25.82B $23.09B 1.12
2023-06-30 $24.05B $23.39B 1.03
2023-03-31 $27.54B $23.13B 1.19
2022-12-31 $29.81B $24.24B 1.23
2022-09-30 $27.95B $23.00B 1.22
2022-06-30 $26.58B $23.17B 1.15
2022-03-31 $25.41B $22.32B 1.14
2021-12-31 $24.31B $23.87B 1.02
2021-09-30 $25.46B $23.73B 1.07
2021-06-30 $23.17B $21.91B 1.06
2021-03-31 $20.51B $26.36B 0.78
2020-12-31 $22.21B $27.33B 0.81
2020-09-30 $20.45B $20.41B 1.00
2020-06-30 $23.29B $22.18B 1.05
2020-03-31 $20.33B $23.48B 0.87
2019-12-31 $21.51B $22.22B 0.97
2019-09-30 $20.29B $20.68B 0.98
2019-06-30 $18.45B $20.09B 0.92
2019-03-31 $19.64B $18.54B 1.06
2018-12-31 $20.44B $22.21B 0.92
2018-09-30 $21.42B $18.59B 1.15
2018-06-30 $18.89B $18.13B 1.04
2018-03-31 $18.70B $16.96B 1.10
2017-12-31 $19.67B $18.61B 1.06
2017-09-30 $22.66B $19.47B 1.16
2017-06-30 $22.76B $18.76B 1.21
2017-03-31 $26.38B $19.82B 1.33
2016-12-31 $25.75B $17.20B 1.50
2016-09-30 $24.20B $15.56B 1.56
2016-06-30 $22.68B $14.92B 1.52
2016-03-31 $23.67B $17.57B 1.35
2015-12-31 $25.05B $19.20B 1.31
2015-09-30 $23.44B $17.58B 1.33
2015-06-30 $23.01B $17.51B 1.31
2015-03-31 $27.39B $20.44B 1.34
2014-12-31 $27.03B $18.40B 1.47
2014-09-30 $28.90B $25.93B 1.12
2014-06-30 $27.45B $17.93B 1.53
2014-03-31 $34.86B $22.47B 1.55
2013-12-31 $29.46B $17.87B 1.65
2013-09-30 $31.02B $18.22B 1.70
2013-06-30 $30.23B $18.40B 1.64
2013-03-31 $28.47B $18.80B 1.51
2012-12-31 $28.32B $18.35B 1.54
2012-09-30 $29.50B $15.58B 1.89
2012-06-30 $29.39B $16.91B 1.74
2012-03-31 $28.01B $16.58B 1.69
2011-12-31 $26.93B $16.25B 1.66
2011-09-30 $27.87B $16.59B 1.68
2011-06-30 $26.14B $15.76B 1.66
2011-03-31 $24.97B $15.66B 1.59
2010-12-31 $23.20B $15.64B 1.48
2010-09-30 $21.49B $17.32B 1.24
2010-06-30 $20.01B $15.42B 1.30
2010-03-31 $21.42B $16.46B 1.30
2009-12-31 $20.38B $15.64B 1.30
2009-09-30 $27.57B $8.03B 3.44
2009-06-30 $27.08B $11.51B 2.35
2009-03-31 $24.06B $13.42B 1.79
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $196.697B $64.168B
Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $796.425B 64.61
Johnson & Johnson (JNJ) United States $379.479B 15.67
AbbVie (ABBV) United States $306.016B 17.09
Novo Nordisk (NVO) Denmark $260.636B 17.65
Roche Holding AG (RHHBY) Switzerland $248.102B 0.00
Novartis AG (NVS) Switzerland $234.183B 14.19
Sanofi (SNY) France $128.587B 12.24
Pfizer (PFE) United States $125.566B 7.12
Bayer (BAYRY) Germany $23.657B 4.39
Innoviva (INVA) United States $1.145B 10.56